OliX Pharmaceuticals Inc Ordinary Shares 226950
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- ₩91,300.00
- Day Range
- ₩84,500.00–90,000.00
- 52-Week Range
- ₩84,000.00–217,000.00
- Bid/Ask
- ₩85,900.00 / ₩86,100.00
- Shares Outstanding
- 22.75M
- Market Cap
- ₩1.99T
- Volume/Avg
- 1,520 / 265,964
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 138.83
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
OliX Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in developing RNA interference (RNAi) technology therapeutics for dermal, ophthalmic and pulmonary diseases. The company’s pipeline products include OLX101, OLX201, OLX301, OLX102, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 67
- Website
- http://www.olixpharma.com
Valuation
|
Metric
|
226950
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.39 |
Price/Sales | 138.83 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
226950
|
|---|---|
Quick Ratio | 11.58 |
Current Ratio | 11.74 |
Interest Coverage | −13.57 |
Quick Ratio
226950
Profitability
|
Metric
|
226950
|
|---|---|
Return on Assets (Normalized) | −18.60% |
Return on Equity (Normalized) | −26.06% |
Return on Invested Capital (Normalized) | −21.81% |
Return on Assets
226950
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|xY!<>$& | LOCK|P$n< | $126B | |||
| Moderna Inc
MRNA
| LOCK|xC@^j&$ | LOCK|&D$ | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&mBW#$% | LOCK|?w&L# | $80B | |||
| argenx SE ADR
ARGX
| LOCK|^P$SPD | LOCK|V^Z | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?mpN&dw | LOCK|>> | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|xTm@W$% | LOCK|JC?j | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|X%%!Y$Vr | LOCK|FHXK | $26B | |||
| Incyte Corp
INCY
| LOCK|y#zc@> | LOCK|^r@ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|ntW>ZkZ | LOCK|%% | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|m&?wYDZ | LOCK|@&S | $14B |
United States